Nausea, vomiting, and diarrhea in North American and RoW patients in (A) LixiLan-O and (B) LixiLan-L
| LixiLan-O | iGlarLixi | iGlar | Lixisenatide | ||||||
| NA n=136 | RoW n=333 | P value | NA n=156 | RoW n=311 | P value | NA n=80 | RoW n=153 | P value | |
| Nausea | 13 (9.6) | 32 (9.6) | 0.986 | 11 (7.1) | 6 (1.9) | 0.020 | 27 (33.8) | 29 (19.0) | 0.016 |
| Vomiting | 7 (5.1) | 8 (2.4) | 0.185 | 4 (2.6) | 3 (1.0) | 0.247 | 9 (11.3) | 6 (3.9) | 0.058 |
| Diarrhea | 14 (10.3) | 28 (8.4) | 0.532 | 9 (5.8) | 11 (3.5) | 0.297 | 12 (15.0) | 9 (5.9) | 0.039 |
| LixiLan-L | iGlarLixi | iGlar | ||||
| NA n=104 | RoW n=261 | P value | NA n=91 | RoW n=274 | P value | |
| Nausea | 14 (13.5) | 24 (9.2) | 0.261 | 1 (1.1) | 1 (0.4) | 0.524 |
| Vomiting | 6 (5.8) | 7 (2.7) | 0.216 | 0 | 2 (0.7) | 0.156 |
| Diarrhea | 5 (4.8) | 11 (4.2) | 0.808 | 5 (5.5) | 5 (1.8) | 0.146 |
Data are n, (%).
iGlar, insulin glargine; iGlarLixi, insulin glargine/lixisenatide; NA, North America; RoW, rest of the world.